Lineage Cell Therapeutics (LCTX) Reports In-Line Q3 EPS

Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $2.27 million versus the consensus estimate of $510 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• TD Cowen cuts Flowserve to Hold, flags guidance reset risk amid Mideast woes
• Hertz cuts guidance, announces notes and stock offerings, shares sink